At a press conference at ESMO 2014, Dr Symonds discusses the results of a phase II trial which showed that for patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival.

Read the news story and watch the interview for more.